UA80426C2 - Pharmaceutical composition comprising arsenite for the treatment of malignancy - Google Patents
Pharmaceutical composition comprising arsenite for the treatment of malignancy Download PDFInfo
- Publication number
- UA80426C2 UA80426C2 UA20041109151A UA20041109151A UA80426C2 UA 80426 C2 UA80426 C2 UA 80426C2 UA 20041109151 A UA20041109151 A UA 20041109151A UA 20041109151 A UA20041109151 A UA 20041109151A UA 80426 C2 UA80426 C2 UA 80426C2
- Authority
- UA
- Ukraine
- Prior art keywords
- arsenite
- tumour
- treatment
- tumor
- tumors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract description 23
- 201000011510 cancer Diseases 0.000 title abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 4
- 230000036210 malignancy Effects 0.000 title abstract 2
- AQLMHYSWFMLWBS-UHFFFAOYSA-N arsenite(1-) Chemical compound O[As](O)[O-] AQLMHYSWFMLWBS-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract description 6
- 239000007787 solid Substances 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 3
- 210000001072 colon Anatomy 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 9
- 208000008839 Kidney Neoplasms Diseases 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 206010061968 Gastric neoplasm Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000985610 Forpus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229940097322 potassium arsenite Drugs 0.000 description 1
- HEQWEGCSZXMIJQ-UHFFFAOYSA-M potassium;oxoarsinite Chemical compound [K+].[O-][As]=O HEQWEGCSZXMIJQ-UHFFFAOYSA-M 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL2002/000231 WO2003086424A1 (en) | 2002-04-10 | 2002-04-10 | Pharmaceutical composition comprising arsenite for the treatment of malignancy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA80426C2 true UA80426C2 (en) | 2007-09-25 |
Family
ID=29244880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20041109151A UA80426C2 (en) | 2002-04-10 | 2002-10-04 | Pharmaceutical composition comprising arsenite for the treatment of malignancy |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20050106262A1 (pt) |
| EP (2) | EP2042182B1 (pt) |
| JP (1) | JP2005525397A (pt) |
| CN (1) | CN1298332C (pt) |
| AP (1) | AP2004003167A0 (pt) |
| AU (2) | AU2002253713B2 (pt) |
| BG (1) | BG66356B1 (pt) |
| BR (1) | BR0215689A (pt) |
| CA (1) | CA2481602C (pt) |
| CY (1) | CY1114422T1 (pt) |
| DK (2) | DK1496918T3 (pt) |
| EC (1) | ECSP045408A (pt) |
| ES (2) | ES2944907T3 (pt) |
| FI (1) | FI1496918T3 (pt) |
| HU (1) | HU230851B1 (pt) |
| IL (2) | IL164470A0 (pt) |
| LT (1) | LT1496918T (pt) |
| MX (1) | MXPA04009898A (pt) |
| NO (1) | NO335317B1 (pt) |
| NZ (1) | NZ536452A (pt) |
| PT (2) | PT2042182E (pt) |
| RO (1) | RO123269B1 (pt) |
| TN (1) | TNSN04198A1 (pt) |
| UA (1) | UA80426C2 (pt) |
| WO (1) | WO2003086424A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070292478A1 (en) * | 2004-08-30 | 2007-12-20 | Popowski Youri | Medical Implant Provided with Inhibitors of Atp Synthesis |
| EP1721615A1 (en) * | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US8945505B2 (en) | 2007-02-02 | 2015-02-03 | Panaphix, Inc. | Use of arsenic compounds for treatment of pain and inflammation |
| US20090246291A1 (en) * | 2008-03-27 | 2009-10-01 | Angelika Burger | Method and compositions for treatment of cancer |
| US20100249210A1 (en) * | 2008-09-30 | 2010-09-30 | Michael Bastiani | Methods and compositions related to dlk-1 and the p38 mapk pathway in nerve regeneration |
| CN102060722B (zh) * | 2009-05-01 | 2014-06-11 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种含砷化合物及其制备方法和用途 |
| RU2568834C2 (ru) * | 2009-09-10 | 2015-11-20 | Коминокс, Инк. | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами |
| KR20120048706A (ko) * | 2009-09-18 | 2012-05-15 | 코미녹스 인코포레이티드 | 뇌종양 치료 방법 |
| CN101695501B (zh) * | 2009-10-10 | 2013-08-14 | 广汉恒宇新材料有限公司 | 一种纳米尺寸亚砷酸的壳聚糖包载体及其制造方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0804928B1 (en) * | 1994-02-18 | 2004-10-20 | Tamara Vasilievna Vorobieva | Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system |
| DK1378240T3 (da) * | 1997-10-15 | 2008-12-08 | Polarx Biopharmaceuticals Inc | Farmaceutiske præparater omfattende arsentrioxid til behandling af multipelt myelom |
| CN1119152C (zh) * | 1998-08-02 | 2003-08-27 | 哈尔滨医科大学第一临床医学院 | 治疗消化系统肿瘤注射液及其应用 |
-
2002
- 2002-04-10 MX MXPA04009898A patent/MXPA04009898A/es unknown
- 2002-04-10 ES ES02722968T patent/ES2944907T3/es not_active Expired - Lifetime
- 2002-04-10 CA CA2481602A patent/CA2481602C/en not_active Expired - Lifetime
- 2002-04-10 AP APAP/P/2004/003167A patent/AP2004003167A0/en unknown
- 2002-04-10 CN CNB028287215A patent/CN1298332C/zh not_active Expired - Lifetime
- 2002-04-10 BR BR0215689-0A patent/BR0215689A/pt not_active Application Discontinuation
- 2002-04-10 WO PCT/NL2002/000231 patent/WO2003086424A1/en active Application Filing
- 2002-04-10 EP EP08168243.7A patent/EP2042182B1/en not_active Expired - Lifetime
- 2002-04-10 DK DK02722968.1T patent/DK1496918T3/da active
- 2002-04-10 DK DK08168243.7T patent/DK2042182T3/da active
- 2002-04-10 FI FIEP02722968.1T patent/FI1496918T3/fi active
- 2002-04-10 NZ NZ536452A patent/NZ536452A/en not_active IP Right Cessation
- 2002-04-10 PT PT81682437T patent/PT2042182E/pt unknown
- 2002-04-10 IL IL16447002A patent/IL164470A0/xx unknown
- 2002-04-10 AU AU2002253713A patent/AU2002253713B2/en not_active Expired
- 2002-04-10 EP EP02722968.1A patent/EP1496918B1/en not_active Expired - Lifetime
- 2002-04-10 ES ES08168243T patent/ES2425418T3/es not_active Expired - Lifetime
- 2002-04-10 JP JP2003583443A patent/JP2005525397A/ja active Pending
- 2002-04-10 RO ROA200400890A patent/RO123269B1/ro unknown
- 2002-04-10 HU HU0500199A patent/HU230851B1/hu unknown
- 2002-04-10 LT LTEPPCT/NL2002/000231T patent/LT1496918T/lt unknown
- 2002-04-10 PT PT27229681T patent/PT1496918T/pt unknown
- 2002-10-04 UA UA20041109151A patent/UA80426C2/uk unknown
-
2004
- 2004-10-08 US US10/962,357 patent/US20050106262A1/en not_active Abandoned
- 2004-10-08 TN TNP2004000198A patent/TNSN04198A1/en unknown
- 2004-10-10 IL IL164470A patent/IL164470A/en active IP Right Grant
- 2004-10-22 NO NO20044573A patent/NO335317B1/no not_active IP Right Cessation
- 2004-11-04 EC EC2004005408A patent/ECSP045408A/es unknown
- 2004-11-09 BG BG108932A patent/BG66356B1/bg unknown
-
2008
- 2008-12-04 AU AU2008255139A patent/AU2008255139B2/en not_active Expired
-
2013
- 2013-08-21 CY CY20131100715T patent/CY1114422T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mitsudomi et al. | Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent | |
| Attene‐Ramos et al. | DNA damage and toxicogenomic analyses of hydrogen sulfide in human intestinal epithelial FHs 74 Int cells | |
| Kim et al. | Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines | |
| Lopez et al. | Microbiota effects on carcinogenesis: initiation, promotion, and progression | |
| Daoud et al. | Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study | |
| Fu et al. | Influence of inflammatory pathway markers on oxidative stress induced by cold stress in intestine of quails | |
| Ma et al. | Correlation between microbes and colorectal cancer: tumor apoptosis is induced by sitosterols through promoting gut microbiota to produce short-chain fatty acids | |
| Mitsui et al. | Antitumor activity of polyoxomolybdate,[NH3Pri] 6 [Mo7O24]· 3H2O, against, human gastric cancer model | |
| Han et al. | Combined impact of fishmeal and tetracycline on resistomes in mariculture sediment | |
| UA80426C2 (en) | Pharmaceutical composition comprising arsenite for the treatment of malignancy | |
| Dougherty et al. | Intestinal bacteria and colorectal cancer: etiology and treatment | |
| Al-Assaf et al. | Mechanism of cadmium induced apoptosis in human peripheral blood lymphocytes: the role of p53, Fas and Caspase-3 | |
| Bhattacharyya et al. | Unconventional DNA-relevant π-stacked hydrogen bonded arrays involving supramolecular guest benzoate dimers and cooperative anion–π/π–π/π–anion contacts in coordination compounds of Co (ii) and Zn (ii) phenanthroline: Experimental and theoretical studies | |
| Cogswell et al. | MAIT cells: partners or enemies in cancer immunotherapy? | |
| Raman et al. | Designing, synthesis and spectral characterization of Schiff base transition metal complexes: DNA cleavage and antimicrobial activity studies | |
| Tantravahi et al. | Evidence for methylation of inactive human rRNA genes in amplified regions | |
| Yang et al. | Water volume influences antibiotic resistomes and microbiomes during fish corpse decomposition | |
| Oral et al. | Anti-growth effect of a novel trans-dichloridobis [2-(2-hydroxyethyl) pyridine] platinum (II) complex via induction of apoptosis on breast cancer cell lines | |
| TW202223100A (zh) | 生物體起源的ｄｎａ甲基化為基礎之性質控制 | |
| Dong et al. | Cytotoxicity analysis of ambient fine particle in BEAS-2B cells on an air-liquid interface (ALI) microfluidics system | |
| Marukhlenko et al. | Chelation of zinc with biogenic amino acids: Description of properties using balaban index, assessment of biological activity on spirostomum ambiguum cellular biosensor, influence on biofilms and direct antibacterial action | |
| Elser et al. | Biological stoichiometry: an ecological perspective on tumor dynamics | |
| Sciaccotta et al. | Potential New Therapies “ROS-Based” in CLL: An Innovative Paradigm in the Induction of Tumor Cell Apoptosis | |
| Lv et al. | MicroRNA-520a-3p suppresses non-small-cell lung carcinoma by inhibition of High Mobility Group Box 1 (HMGB1). | |
| Wang et al. | Species-specific effects of arsenic on the soil collembolan gut microbiota |